Shanghai, China
Oricell Therapeutics, founded in 2015, is focused on the development of cutting-edge immunotherapies. Headquartered in China, the company is committed to creating drugs that not only demonstrate strong efficacy but are also affordable. Their mission is to address unmet clinical needs worldwide and establish themselves as a leader in tumor immunotherapy.
On February 28, 2023, the company secured a $45.00M Series B investment. This significant funding round was backed by prominent investors such as Qiming Venture Partners, Qatar Investment Authority, RTW Investments, and C&D Emerging Investment. This investment not only highlights the company's potential for growth but also demonstrates strong validation from esteemed financial entities.
Given its novel approach to drug development, commitment to affordability, and support from reputable investors, Oricell Therapeutics represents a compelling opportunity for stakeholders seeking to invest in the future of global healthcare and biotechnology innovation.
